List of Excipients in Branded Drug DICLOFENAC SODIUM MISOPROSTOL

« Back to Dashboard

Generic Drugs Containing DICLOFENAC SODIUM MISOPROSTOL

Company	Ingredient	NDC	Excipient
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	CARNAUBA WAX
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	CELLULOSE, MICROCRYSTALLINE
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	CROSPOVIDONE
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	GLATIRAMER ACETATE
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	HYPROMELLOSE
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	LACTOSE MONOHYDRATE
Proficient Rx LP	diclofenac sodium and misoprostol	71205-865	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM MISOPROSTOL?

# Of NDCs	Excipient
5	CARNAUBA WAX
5	CELLULOSE, MICROCRYSTALLINE
5	CROSPOVIDONE
1	GLATIRAMER ACETATE
5	HYPROMELLOSE
5	LACTOSE MONOHYDRATE
5	MAGNESIUM STEARATE

Diclofenac Sodium Misoprostol Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Diclofenac sodium/misoprostol is a technically differentiated fixed-dose oral product. The commercial value depends less on the active ingredients, whose core patent protection has expired, than on controlled release, moisture protection, dose uniformity, enteric performance, and regulatory positioning. The principal product is Arthrotec, originally developed by G.D. Searle and now associated with Pfizer. It combines diclofenac sodium, an NSAID, with misoprostol, a prostaglandin E1 analogue intended to reduce NSAID-associated gastric ulcer risk.

The strongest commercial opportunities are generic or reformulated oral tablets using robust dual-release architecture, improved packaging, lower manufacturing cost, and differentiated dosage strengths. Biosimilar development is not relevant because both active ingredients are synthetic small molecules.

What is diclofenac sodium/misoprostol and how does the dosage form work?

Diclofenac sodium/misoprostol is an oral fixed-dose combination available in strengths containing either 50 mg or 75 mg of diclofenac sodium with 200 micrograms of misoprostol. The reference product is Arthrotec delayed-release tablets. FDA labeling describes a dosage form designed to deliver misoprostol in the upper gastrointestinal tract while delaying diclofenac release through enteric protection [1].

Product attribute	Commercial relevance
Active ingredients	Diclofenac sodium and misoprostol
Typical strengths	50 mg/200 mcg and 75 mg/200 mcg
Dosage form	Oral delayed-release tablet
Diclofenac function	Analgesic and anti-inflammatory NSAID
Misoprostol function	Gastroprotective prostaglandin analogue
Primary technical challenge	Separate release profiles in one solid dosage form
Key stability concern	Misoprostol sensitivity to moisture and heat
Main regulatory pathway for copies	ANDA, subject to reference-product requirements
Biosimilar exposure	None

Diclofenac must generally be protected from release in the stomach to reduce local gastric exposure and to control absorption. Misoprostol requires earlier release. A conventional homogeneous tablet is therefore poorly suited to the product unless the excipient system creates distinct release behavior for the two ingredients.

What excipient architecture is used for diclofenac sodium/misoprostol?

The most defensible formulation strategy is a dual-phase or multiparticulate system in which misoprostol is available for immediate release and diclofenac is incorporated into enteric-coated particles or granules.

Misoprostol immediate-release phase

Misoprostol is present at a very low dose relative to the tablet mass. The formulation must provide content uniformity at approximately 200 micrograms per unit while avoiding excessive adsorption or migration during granulation, coating, and storage.

Potential excipient classes include:

Excipient function	Candidate classes	Strategic purpose
Diluent	Lactose, microcrystalline cellulose, mannitol	Supports tablet mass and content uniformity
Binder	Povidone, copovidone, hydroxypropyl cellulose	Controls granule strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid misoprostol release
Lubricant	Magnesium stearate, sodium stearyl fumarate	Supports compression and ejection
Stabilization	Low-moisture excipient system, protective coating, desiccant packaging	Reduces degradation risk
Uniformity aid	Ordered mixing or preblend carrier	Limits low-dose segregation

The formulation should minimize water exposure. A dry granulation or low-moisture wet-granulation process may be preferable to a conventional aqueous process, depending on the selected misoprostol concentrate and stability data.

Diclofenac enteric-release phase

Diclofenac sodium can be incorporated into coated granules, pellets, beads, or compressed coated particles. The enteric layer generally relies on pH-dependent polymers such as methacrylic acid copolymers, cellulose acetate phthalate, or polyvinyl acetate phthalate. Plasticizers, anti-tacking agents, and pore-control materials are required to produce a reproducible coating.

Typical excipient functions include:

• Enteric polymer for gastric resistance.
• Plasticizer such as triethyl citrate or polyethylene glycol.
• Anti-tacking agent such as talc.
• Subcoat or seal coat to isolate diclofenac from the enteric polymer and protect the core.
• Filler and binder system compatible with compression.
• Disintegrant configured to release coated diclofenac particles after the enteric layer dissolves.

The manufacturing process must prevent rupture of the enteric coating during final compression. A high-performance coating process alone is insufficient if compression creates cracks, flattening, or abrasion.

What excipients create the largest technical barriers?

The highest-value excipient decisions concern moisture, coating integrity, and release separation.

Moisture control

Misoprostol degradation can be accelerated by moisture and elevated temperature. Moisture-sensitive excipients, aqueous coating steps, and hygroscopic packaging components can reduce shelf life. The preferred commercial package is likely a high-barrier blister or bottle with a validated desiccant system. HDPE bottles with induction seals may be suitable, but blister packaging can provide stronger unit-dose moisture protection.

Low-dose uniformity

A 200-microgram misoprostol load creates a more difficult content-uniformity problem than the larger diclofenac load. Direct blending can produce segregation because of differences in particle size, density, and surface properties. A concentrated misoprostol premix, ordered mixing, spray layering, or controlled granulation can improve uniformity.

Enteric coating durability

The diclofenac component must survive compression and packaging. Excessively brittle films can crack during tablet manufacture. Excessively flexible films can delay release in the intestine or alter dissolution after storage. Polymer grade, plasticizer concentration, coating weight gain, curing conditions, and core hardness are critical process variables.

Excipient compatibility

The formulation should be screened for:

• Misoprostol adsorption to high-surface-area excipients.
• Interaction between alkaline or acidic excipients and enteric polymers.
• Lubricant effects on wetting and dissolution.
• Moisture transfer between tablet phases.
• Migration of low-molecular-weight stabilizers or coating components.
• Changes in dissolution after accelerated aging.

The formulation target is not simply a fast-disintegrating tablet. It is a tablet with immediate misoprostol release, delayed diclofenac release, low moisture uptake, and stable performance after compression and storage.

What formulations are protected by the original product strategy?

The principal technical concept is a fixed-dose formulation that separates the release profiles of diclofenac and misoprostol. Historically, protection for the product would have been directed to the combination, dosage form, coating arrangement, manufacturing process, and therapeutic use rather than to the unmodified active ingredients alone.

The original combination patents and related formulation rights have reached the end of their normal U.S. patent terms. Current competitive barriers are therefore more likely to arise from:

• FDA requirements for pharmaceutical equivalence.
• Complex dissolution matching.
• Low-dose content uniformity.
• Stability and packaging validation.
• Manufacturing scale-up.
• Product liability exposure associated with NSAID and pregnancy warnings.
• Regulatory differences between immediate-release and delayed-release presentations.

A current freedom-to-operate review must examine active patents in each target jurisdiction, including formulation, manufacturing, coating, packaging, and use claims. The FDA Orange Book remains the primary U.S. source for listed patents and exclusivity associated with an approved reference product [2].

When does diclofenac sodium/misoprostol lose exclusivity?

Core active-ingredient exclusivity has expired. Arthrotec was approved in the United States in the 1990s, and the original combination and formulation patent terms would have expired years ago under standard U.S. patent-term rules.

Exclusivity category	Current commercial assessment
Diclofenac sodium composition	Expired
Misoprostol composition	Expired
Original fixed-dose combination	Historical protection expired
FDA new chemical entity exclusivity	Expired
Current market barrier	Formulation execution and regulatory approval
Biosimilar exclusivity	Not applicable
Generic entry route	ANDA or, for a materially different product, 505(b)(2)

The precise current Orange Book record must be checked against the latest FDA publication because listed patents, delisting events, and reference-product marketing status can change. The commercial conclusion remains unchanged: the product is a mature small-molecule combination with no obvious long-term exclusivity moat based solely on the active ingredients.

What is the Orange Book and Paragraph IV status?

Generic applicants may challenge listed patents through an ANDA Paragraph IV certification. For diclofenac sodium/misoprostol, the commercial significance of a new Paragraph IV challenge depends on whether any unexpired formulation or method-of-use patents remain listed against the reference product.

The likely risk profile is:

1. Historical core patents are expired.
2. Any current patent exposure would be claim-specific and could involve a formulation, coating, manufacturing step, or method of use.
3. A Paragraph IV filing could create litigation risk even where the underlying patent estate is narrow.
4. A first-filer opportunity would depend on the current Orange Book record and the filing status of competing ANDAs.
5. A generic applicant may avoid some risk through a non-infringing formulation while maintaining pharmaceutical equivalence.

The reference product also carries substantial labeling constraints. NSAID warnings include cardiovascular and gastrointestinal risks. Misoprostol is contraindicated in pregnancy because of its abortifacient and uterotonic effects [1]. A generic product must reproduce applicable labeling and satisfy bioequivalence and dissolution requirements.

How strong is the patent estate for diclofenac sodium/misoprostol?

The patent estate is likely weak as a barrier to conventional generic entry but stronger as a technical barrier to high-quality replication.

Estate component	Strength assessment
Active ingredients	Low
Original combination concept	Low after expiration
Conventional tablet formulation	Low to moderate
Dual-release architecture	Moderate technical complexity
Enteric coating process	Moderate, depending on claim scope
Moisture-protective packaging	Low to moderate
Manufacturing know-how	Moderate
Regulatory and quality documentation	Moderate
Biosimilar exclusivity	None

Patent strength should not be confused with development difficulty. A competitor may face substantial formulation work even when no blocking patent remains. Trade secrets involving coating parameters, granulation order, premix preparation, and packaging configuration may have more practical importance than expired patent claims.

Which companies are challenging the product and what is the competitive landscape?

Competition is primarily between the originator, generic manufacturers, contract development organizations, and suppliers of specialized excipients and packaging systems.

The relevant competitor groups are:

• Generic manufacturers seeking ANDA approval for diclofenac sodium/misoprostol delayed-release tablets.
• Companies offering diclofenac products without misoprostol, which compete on price but do not provide the same fixed-dose gastroprotective positioning.
• Developers of alternative NSAID and gastroprotective combinations.
• Contract manufacturers with multiparticulate coating and low-dose blending capabilities.
• Excipient suppliers offering enteric polymers, plasticizers, coating systems, and moisture-barrier materials.

No biosimilar competitor exists. The competitive comparison is between generic fixed-dose products and separate-prescription regimens using diclofenac plus a proton-pump inhibitor, H2 antagonist, or other gastroprotective therapy.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can capture value through formulation systems rather than commodity materials.

High-value opportunity areas

1. Ready-to-use enteric coating systems
   Prequalified polymer, plasticizer, pigment, and anti-tacking systems can shorten development and reduce scale-up risk.

2. Low-moisture direct-compression platforms
   A carrier system that improves misoprostol distribution without aqueous processing would address a central formulation problem.

3. Moisture-barrier packaging
   Blister laminates, desiccant systems, and high-barrier bottle closures can improve stability and support longer shelf life.

4. Multiparticulate compression aids
   Excipients that protect coated pellets during compression can reduce coating damage and dissolution failures.

5. Analytical and quality-by-design packages
   Suppliers that provide compatibility data, extractables information, and dissolution support can become embedded in the customer’s regulatory file.

6. Lifecycle reformulation
   Smaller tablets, improved swallowability, reduced tablet weight, or more robust manufacturing may support a 505(b)(2) strategy if the clinical and regulatory differences are material.

The strongest opportunity is a validated platform that combines low-dose uniformity, rapid misoprostol release, delayed diclofenac release, and high moisture resistance.

What manufacturing and intellectual-property barriers remain?

The principal barriers are process-specific:

• Uniform incorporation of misoprostol at microgram scale.
• Avoidance of aqueous exposure during granulation and coating.
• Prevention of enteric-film damage during compression.
• Reproducible dissolution across multiple strengths.
• Stability under long-term and accelerated conditions.
• Protection against moisture ingress during distribution.
• Demonstration of pharmaceutical equivalence to the reference product.
• Management of warning-heavy labeling and pregnancy contraindications.

Geographic expansion also creates differences in regulatory expectations. The United States requires ANDA-based pharmaceutical equivalence and bioequivalence for a generic product. European authorities apply their own requirements for quality, bioequivalence, and risk management. Patent status must be reviewed separately in the United States, European Union, Canada, Japan, and other target markets.

What patent litigation and settlement risks affect the product?

The product’s mature status reduces the likelihood of major originator litigation based on foundational patents. Litigation risk can still arise from:

• A newly listed formulation patent.
• A method-of-use patent covering NSAID ulcer prevention.
• Alleged infringement of coating or manufacturing claims.
• Patent certification disputes involving a generic applicant.
• Product liability litigation related to gastrointestinal bleeding, cardiovascular events, or pregnancy exposure.

No material current settlement agreement should be assumed without reviewing the relevant court docket, FDA records, and company disclosures. Historical settlements involving expired patents have limited predictive value for current market entry.

How does diclofenac sodium/misoprostol compare with separate diclofenac and gastroprotection?

Factor	Fixed-dose diclofenac/misoprostol	Separate diclofenac plus gastroprotection
Pill burden	Lower	Higher
Dose flexibility	Limited by fixed ratio	Greater
Formulation complexity	High	Lower for each individual product
Misoprostol tolerability	May limit use because of diarrhea and cramping	Can be avoided or separately adjusted
Generic development	Requires dual-release matching	More straightforward
Packaging needs	High moisture-control burden	Product-specific
Differentiation	Combination convenience and labeled gastroprotection	Prescriber flexibility
Commercial weakness	Pregnancy contraindication and tolerability	Adherence and pill burden

The fixed-dose product is most attractive where adherence, NSAID-associated ulcer risk, and convenience outweigh the tolerability and dosing limitations of misoprostol.

Key Takeaways

• Diclofenac sodium/misoprostol is a mature small-molecule combination with expired core active-ingredient and foundational combination protection.
• The formulation challenge is dual release: immediate misoprostol delivery and delayed diclofenac release.
• The highest-value excipient technologies involve enteric coating, low-moisture processing, low-dose uniformity, compression protection, and barrier packaging.
• Generic entry is more likely to be constrained by formulation execution and regulatory equivalence than by a strong active patent estate.
• Biosimilar risk is irrelevant; the principal threat is conventional generic competition.
• A ready-to-use excipient and packaging platform could support generic ANDA development, lifecycle reformulation, or regional licensing.
• Any current Paragraph IV or Orange Book assessment requires a live review of FDA records and patent litigation dockets.

FAQs

Is diclofenac sodium/misoprostol still commercially attractive?

Yes, but primarily as a low-cost generic or formulation-platform opportunity. The product has limited active-ingredient exclusivity but retains technical differentiation through its dual-release dosage form.

Which excipient is most important for diclofenac sodium/misoprostol?

No single excipient determines performance. The most important system is the combination of an enteric polymer, a compatible plasticizer, a compression-protective particulate structure, and a moisture-control strategy for misoprostol.

Can diclofenac sodium/misoprostol be developed as a standard immediate-release tablet?

A standard homogeneous immediate-release tablet would not reproduce the intended separation of diclofenac and misoprostol release. It could require a different regulatory and clinical strategy.

Is a 505(b)(2) application possible for a reformulated product?

Potentially, if the proposed product differs materially from the reference product in dosage form, release profile, strength, route, or labeling and the applicant can support the change with appropriate data. A conventional equivalent generic would generally be evaluated through the ANDA pathway.

What is the main failure mode during commercial scale-up?

The main failure modes are misoprostol content-uniformity variation, moisture-related degradation, enteric-coating damage during compression, and dissolution drift after stability storage.

References

1. U.S. Food and Drug Administration. (n.d.). Arthrotec- diclofenac sodium and misoprostol tablet, delayed release: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2015). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.